TY - JOUR
T1 - Megestrol acetate for treatment of advanced carcinoma of the prostate
AU - Johnson, Douglas E.
AU - Kaesler, Kelly E.
AU - Ayala, Alberto
PY - 1975/1/1
Y1 - 1975/1/1
N2 - Thirteen men, ranging in age from 53 to 73 years and with previously untreated metastatic carcinoma of the prostate, received megestrol acetate (a synthetic progestin) in doses of 120 mg daily. A beneficial clinical response with a mean duration of 47 weeks was achieved in 12 patients (92%). When relapse developed in 8 patients, a secondary response was readily obtained by orchiectomy. The results suggest that a staged hormonal approach, using progestin therapy initially, may offer additional palliation in treating patients with metastatic prostatic carcinoma.
AB - Thirteen men, ranging in age from 53 to 73 years and with previously untreated metastatic carcinoma of the prostate, received megestrol acetate (a synthetic progestin) in doses of 120 mg daily. A beneficial clinical response with a mean duration of 47 weeks was achieved in 12 patients (92%). When relapse developed in 8 patients, a secondary response was readily obtained by orchiectomy. The results suggest that a staged hormonal approach, using progestin therapy initially, may offer additional palliation in treating patients with metastatic prostatic carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0016687314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016687314&partnerID=8YFLogxK
U2 - 10.1002/jso.2930070103
DO - 10.1002/jso.2930070103
M3 - Article
C2 - 1177459
AN - SCOPUS:0016687314
SN - 0022-4790
VL - 7
SP - 9
EP - 15
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 1
ER -